Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996 Dec 1;98(11):2616-22.
doi: 10.1172/JCI119082.

Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis

Affiliations
Comparative Study

Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis

M Boirivant et al. J Clin Invest. .

Abstract

Lamina propria (LP) T cells respond poorly to a proliferative stimulus delivered via TCR/CD3 pathway, but retain considerable ability to respond to a stimulus delivered via CD2 costimulatory or accessory pathway. In the present study, we showed first that unstimulated LP T cells, as compared to unstimulated peripheral blood (PB) T cells, exhibit an increased level of apoptosis which is further increased following CD2 pathway stimulation, but not following via TCR/CD3 pathway stimulation. We next showed that IL-2 had a sparing effect on apoptosis of unstimulated LP T cells in that IL-2 decreased and anti-IL-2 increased apoptosis of these cells; in contrast, IL-2 had no effect on apoptosis of CD2-pathway stimulated cells. Finally, we showed that increased apoptosis of LP T cells induced by CD2-pathway stimulation is inhibited when Fas antigen is blocked by a nonstimulatory anti-Fas antibody. These studies suggest that LP T cells are characterized by increased susceptibility to Fas-mediated apoptosis most due to a downstream change in the Fas signaling pathway. Given that IFN-gamma secretion is significantly increased in LP T cells in which apoptosis is inhibited, this feature of LP T cells may represent a mechanism of regulating detrimental immune responses in the mucosal environment.

PubMed Disclaimer

References

    1. J Clin Invest. 1977 May;59(5):966-74 - PubMed
    1. J Clin Invest. 1995 Jun;95(6):2945-53 - PubMed
    1. J Clin Invest. 1989 Jun;83(6):1827-33 - PubMed
    1. Gastroenterology. 1989 Dec;97(6):1562-84 - PubMed
    1. Eur J Immunol. 1990 Oct;20(10):2339-42 - PubMed

Publication types